Description
NKTR-102 is an antibody-drug conjugate that combines irinotecan with a polyethylene glycol polymer to create a long-acting topoisomerase I inhibitor for colorectal cancer treatment. The drug has been evaluated in Phase 1 and Phase 2 trials specifically for patients with metastatic colorectal cancer, including those with KRAS mutations who are irinotecan-naïve. Clinical trials have tested NKTR-102 both as monotherapy and in combination with cetuximab for refractory solid tumors and advanced colorectal cancer.
Mechanism of Action
NKTR-102 uses a proprietary polymer conjugation technology to deliver irinotecan in a sustained manner, allowing the active metabolite SN-38 to accumulate preferentially in tumor tissues. The polyethylene glycol carrier extends the drug's half-life and modifies its distribution, potentially improving the therapeutic index compared to conventional irinotecan by reducing peak concentrations while maintaining antitumor activity.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Antibody-Drug Conjugate |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.